Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC7 | O00311 | 5/20 | 0.57 |
| ▸ | CCNE1 | P24864 | 5/20 | 0.57 |
| ▸ | CDK2 | P24941 | 5/20 | 0.57 |
| ▸ | ROCK1 | Q13464 | 5/20 | 0.57 |
| ▸ | DBF4 | Q9UBU7 | 5/20 | 0.57 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 8/20 | 0.39 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.39 |
| ▸ | ACACB | O00763 | 2/20 | 0.37 |
| ▸ | JAK1 | P23458 | 1/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.36 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10238503 | 0.82 | CDC7 (0.45) | CDC7CCNE1CDK2ROCK1DBF4 | |
| SCHEMBL613190 | 0.72 | CDC7 (0.73) | CDC7CCNE1CDK2ROCK1DBF4 | |
| SCHEMBL613283 | 0.68 | ROCK1 (0.62) | CDC7CCNE1CDK2ROCK1DBF4 | |
| SCHEMBL614189 | 0.66 | CDK2 (0.57) | CDC7CCNE1CDK2ROCK1DBF4 | |
| SCHEMBL613548 | 0.66 | CDC7 (0.70) | CDC7CCNE1CDK2ROCK1DBF4 | |
| SCHEMBL8019758 | 0.65 | GPR119 (0.47) | GPR119ROCK2ACACBJAK1 | |
| SCHEMBL940091 | 0.65 | MEN1 (0.49) | GPR119ROCK2ACACBJAK1 | |
| SCHEMBL611766 | 0.65 | ROCK1 (0.58) | CDC7CCNE1CDK2ROCK1DBF4 | |
| SCHEMBL11989494 | 0.64 | AKT2 (0.56) | GPR119ROCK2JAK1 | |
| SCHEMBL10238496 | 0.64 | CDC7 (0.62) | CDC7CCNE1CDK2ROCK1DBF4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2403857-B1 | THIENOPYRIMIDINE AS CDC7 KINASE INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2013-12-04 | — | — | EP | disclosed |
| US-20120040981-A1 | THIENOPYRIMIDINE AS CDC7 KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-02-16 | — | — | US | disclosed |
| WO-2010101302-A1 | THIENOPYRIMIDINE AS CDC7 KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040981-A1 | THIENOPYRIMIDINE AS CDC7 KINASE INHIBITORS | CDC7, CDK7, DTYMK | CDC7 1/4885CCNE1 158/4885CDK2 41/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.